SYNERGY MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY™ BP Stent Clinical Overview

The SYNERGY™ Bioabsorbable Polymer (BP) Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.

Contact Us

Explore

 

Heal With Confidence: Leading in Complex Patients

SYNTAX II Trial
The SYNTAX II Trial utilizing the SYNERGY™ BP Stent, physiological assessment, IVUS guidance, and contemporary state-of-the art PCI techniques demonstrated CABG-like outcomes in patients with three-vessel disease at 3-years.*†¹

Low rates of revascularization, peri-procedural MI, and acute ST suggests that contemporary technologies might help in reducing procedural related complications.

* Angiographically detected.
† The safety and efficacy of the SYNERGY™ Stent has not been established in patients with 3 vessel disease or CTO lesions
‡ Patient oriented composite endpoint (POCE) is a composite of all-cause death, any stroke, any MI, and any revascularization..

Heal With Confidence: Leading in Complex Patients

‡ Patient oriented composite endpoint (POCE) is a composite of all-cause death, any stroke, any MI, and any revascularization.

 

Consistently Low ST Rates

Kang Network Meta-Analysis
SYNERGY™ BP Stent ranked #1 for the lowest relative risk of def/prob ST At 1-year. §²
 
Kang Network Meta-Analysis

§ Caution should be taken in interpreting study results, as some stents had limited numbers of comparisons, and some of the studies had a potential risk of bias. All PtCr-EES stents, also includes PROMUS Element and PROMUS Element Plus. Def/prob ST was available in 110 studies and 111,088 patients.

SCAAR Registry
Lowest ST rate compared to newer generation DES (n-DES) despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI, and 3VD.* **³
 
SCAAR Registry

* Angiographically detected.
** Some patients in the SCAAR study were treated for either Left Main, CTO, or multi-vessel disease but did not show statistical significance. The safety and efficacy of the SYNERGY™ BP Stent for those uses has not been established. A total of 7,886 SYNERGY™ stents and 64,429 other n-DES (BioMatrix, N=1,953; Orsiro, N=4,946; Promus Element Plus, N=2,543; Promus PREMIER, N=20,414; Xience Xpedition, N=7,971, Resolute/Resolute Integrity, N=19,021; Ultimaster, N=1,156; and Resolute Onyx, N=6,425) were implanted in 42,357 procedures.

 

Leading On Studying Short DAPT

Supporting well-constructed prospective Short DAPT clinical trials with over 5,000 patients to study the SYNERGY™ BP Stent in various complex patient populations
EVOLVE Short DAPT Trial: Primary Endpoint Results 12 Months Post-DAPT Discontinuation
Studies the safety of discontinuing DAPT at 3-months in high bleeding risk patients using the SYNERGY™ BP Stent.
 

ARC definite/probable ST
vs. performance goal4

Low ARC definite/probable

0.2% ST Rate

3-month DAPT with SYNERGY™ BP Stent

ARC definite/probable ST vs. performance goal chart

†† Patients with respective event or sufficient follow-up included in the denominator.

Adjusted death/MI with 3-month DAPT
vs. historical control5

3-month DAPT with SYNERGY™ BP Stent

Non-Inferior

to 12-month DAPT in a historical control

Adjusted death/MI with 3-month DAPT vs. historical control chart

†† Patients with respective event or sufficient follow-up included in the denominator.
‡‡ Worst-case scenario analysis: site-reported MI in control group between 0-12 m assumed within 0-3 m if not CEC adjudicated. Death/MI endpoint is comprised of HBR subjects from HCRI DAPT Study and PROMUS Element post-approval studies that meet the EVOLVE Short DAPT criteria.

 
SENIOR Trial: Safety Data at 2-Years
The SYNERGY™ BP Stent continued to show superior results versus REBEL BMS with short BMS-like DAPT regimen at 2-years.

All patients6

All patients chart

*** Bleeding Academic Research Consortium (BARC).

1-month DAPT discontinuation cohort§§ 6

1-month DAPT discontinuation cohort

§§ In patients eligible for 1-month DAPT in this study. Please review the SYNERGY™ DFU for full instructions on DAPT.

 
Product Overview

Product Overview

Discover best-in-class strength, unmatched overexpansion, maximum visibility and uniform lesion scaffolding.

Button
Mega Strength

Mega Strength

Learn why we created a stent purpose-built for large proximal vessels.

Button
Optimal Healing

Optimal Healing

Find out how synchronous drug elution and polymer absorption enables early healing.

Button

Request a rep

Fill out a quick form and one of our sales representatives will be in touch.

Request a rep
Top